Eclipse Advises on Sale of Lucis Pharma to Rosemont Pharmaceuticals

Eclipse Corporate Finance is pleased to announce the successful sale of Lucis Pharma, a specialist pharmaceutical business, to Rosemont Pharmaceuticals, backed by Inflexion.

Lucis Pharma focuses on the development and licensing of novel treatments, supporting innovation across niche therapeutic areas. The acquisition will enhance Rosemont’s specialist portfolio and expand its capabilities in complex medicines.

Strategic Advice in a Technical Transaction

This was a bilateral deal, negotiated directly between Lucis and Rosemont. Eclipse played a key role in:

• Securing significant value for the shareholders

• Navigating a complex completion mechanism with multiple technical adjustments

• Streamlining the deal process to reduce delays and prevent friction between parties

Comment from Eclipse

“This transaction required careful planning and technical structuring to ensure a clean, high-value exit for the founders. We're proud to have helped unlock that outcome.”

What This Deal Reflects

This transaction highlights continued investor interest in UK-based specialist pharma businesses, especially those with:

• IP-backed product pipelines

• Licensing models with international potential

• Lean, expert teams delivering high-value innovation

Eclipse Corporate Finance specialises in advising healthcare and life sciences businesses on company sales and private equity investment. We combine deep sector insight with hands-on execution support, ensuring a founder-first approach in complex M&A.

Planning your own exit? Read our guide to when to start preparing to sell your healthcare business.